Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Shionogi & Co ( (JP:4507) ) is now available.
Shionogi reported solid growth for the nine months ended 31 December 2025, with revenue up 8.1% year-on-year to ¥360.7 billion and operating profit rising 15.1% to ¥148.7 billion. Profit attributable to owners of the parent climbed 18.3% to ¥158.2 billion, lifting basic earnings per share to ¥185.95, calculated to reflect a 3-for-1 stock split implemented in October 2024. The company’s financial position remained strong, with total assets of ¥1.73 trillion and an equity ratio of 87.6%, while it maintained its dividend stance, confirming an annual payout forecast of ¥66 per share for the year ending March 31, 2026. Shionogi left its full-year guidance unchanged, targeting revenue of ¥500 billion and profit attributable to owners of the parent of ¥188 billion, and it expanded its consolidation scope by newly including Torii Pharmaceutical as a subsidiary, a move that may strengthen its product base and domestic market presence.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen3466.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange, focused on researching, developing and marketing prescription drugs, with a historical strength in infectious disease treatments and a broad portfolio of innovative therapies for global markets.
Average Trading Volume: 2,929,620
Technical Sentiment Signal: Buy
Current Market Cap: Yen2770.5B
Learn more about 4507 stock on TipRanks’ Stock Analysis page.